Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022607 | 0.85 | SMN1; SMN2 (0.57) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL27780337 | 0.84 | KEAP1 (0.49) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL10290473 | 0.83 | HSD17B1 (0.56) | SMN1; SMN2TSHRCASP1L3MBTL1MEN1 | |
| SCHEMBL16041940 | 0.79 | KEAP1 (0.54) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL3632865 | 0.78 | KEAP1 (0.50) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL2578143 | 0.77 | CXCL8 (0.57) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL29497752 | 0.77 | CXCL8 (0.57) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL2558133 | 0.76 | HSD17B10 (0.66) | MAPTPOLBALDH1A1KDM4EMAPK1 | |
| SCHEMBL27310825 | 0.76 | FLT1 (0.44) | SMN1; SMN2TSHRCASP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1373062 | 0.76 | CXCL8 (0.55) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3058941-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2194987-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8871802-B2 | Naphthoquinones for disease therapies | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024818-A1 | NOVEL ANPHTHOQUINONES FOR DISEASE THERAPIES | ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) | 2012-03-01 | — | — | WO | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2194987-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009036059-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | KEAP1 313/4885NFE2L2 91/4885CXCL8 1536/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | KEAP1 336/4885NFE2L2 82/4885CXCL8 1520/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | KEAP1 221/4885NFE2L2 65/4885CXCL8 1686/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | KEAP1 313/4885NFE2L2 91/4885CXCL8 1536/4885 |
| US-20130150437-A1 | NAPHTHOQUINONES FOR DISEASE THERAPIES | NQO1, NME2, CYP27B1 | KEAP1 12/4885NFE2L2 5/4885CXCL8 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.